Sagimet Biosciences (STU:0O2) Net Income From Continuing Operations: €-37.39 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:0O2 Sagimet Biosciences Inc STU:0O2
38 GF Score
Price €6.40
GF Value €5.69
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is Sagimet Biosciences Net Income From Continuing Operations?

Sagimet Biosciences STU:0O2 -4.48% 38 Net Income From Continuing Operations is €-37.39 Mil as of Mar. 2026. GuruFocus rates STU:0O2 with a GF Score™ of 38/100 and a GF Value™ of €5.69 (Modestly Overvalued). The stock has 2 warning signs investors should review.

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Sagimet Biosciences's net income from continuing operations for the three months ended in Mar. 2026 was €-9.21 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Mar. 2026 was €-37.39 Mil.

Sagimet Biosciences Net Income From Continuing Operations Historical Data

* Premium members only.

The historical data trend for Sagimet Biosciences's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sagimet Biosciences Net Income From Continuing Operations Chart

Sagimet Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Income From Continuing Operations
Get a 7-Day Free Trial -21.63 -28.79 -25.56 -43.52 -43.59

Sagimet Biosciences Quarterly Data
Dec20 Mar21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Net Income From Continuing Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -16.81 -9.01 -11.00 -8.17 -9.21
STU:0O2
38GF Score
Sagimet Biosciences Inc STU:0O2
Net Income From Continuing Operations is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sagimet Biosciences Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-37.39 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Net Income From Continuing Operations of €-37.39 Mil mean?
Sagimet Biosciences (STU:0O2) has a Net Income From Continuing Operations of €-37.39 Mil as of Mar. 2026. The total net income from continuing operations as record on a company's cash-flow statement. View historical data for Sagimet Biosciences and its competitors.
Is Sagimet Biosciences' Net Income From Continuing Operations too high?
Sagimet Biosciences' current Net Income From Continuing Operations is €-37.39 Mil. Overall, Sagimet Biosciences has a GF Score™ of 38/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sagimet Biosciences' Net Income From Continuing Operations compare to EDIT and AUTL?
Sagimet Biosciences' Net Income From Continuing Operations of €-37.39 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Income From Continuing Operations for a Biotechnology company?
A good Net Income From Continuing Operations depends on the Biotechnology industry context. However, Net Income From Continuing Operations should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Income From Continuing Operations mean?
A high Net Income From Continuing Operations can signal that a stock is expensive relative to its fundamentals. The total net income from continuing operations as record on a company's cash-flow statement. View historical data for Sagimet Biosciences and its competitors. Sagimet Biosciences's current Net Income From Continuing Operations is €-37.39 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sagimet Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Sagimet Biosciences (STU:0O2) is currently considered Modestly Overvalued. The stock's GF Value™ is €5.69, compared to a current price of €6.40 — trading 12.5% above its estimated fair value. The current Net Income From Continuing Operations is €-37.39 Mil. Sagimet Biosciences' overall GF Score™ is 38/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Income From Continuing Operations calculated?
Net Income From Continuing Operations is calculated from a company's financial statements. For Sagimet Biosciences (STU:0O2), the current Net Income From Continuing Operations is €-37.39 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sagimet Biosciences (STU:0O2) Overvalued in 2026?

Based on GuruFocus' analysis, Sagimet Biosciences stock appears to be overvalued. The current stock price of €6.40 is trading 12.5% above its estimated GF Value™ of €5.69. GuruFocus considers Sagimet Biosciences to be Modestly Overvalued.

Key valuation signals for STU:0O2:

  • Net Income From Continuing Operations: €-37.39 Mil
  • GF Value™: €5.69 vs. price of €6.40 (12.5% above fair value)
  • GF Score™: 38/100 with 2 warning signs

No single metric tells the full story. See the STU:0O2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sagimet Biosciences Business Description

Other Exchanges SGMT:USA
Address 155 Bovet Road, Suite 303, San Mateo, CA, USA, 94402
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.
38GF Score

Get the complete analysis for STU:0O2

Net Income From Continuing Operations is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.40
Price
€5.69
GF Value